{
  "id": "multiple-myeloma-by-site",
  "display_name": "Multiple Myeloma by Site",
  "cohort": "Multiple Myeloma, RRMM, by Treatment Site (2024–2025)",
  "insight_type": "Site-Specific Margin Analysis",
  "summary": "Significant variation in Daratumumab regimen utilization across sites. Site A leads with 52% usage while Site D lags at only 21%, representing a $280,000 annual opportunity for optimization.",
  "chart": {
    "type": "bar",
    "unit": "site",
    "data": [
      { "name": "Site A", "value": 52, "gap": 18, "highlight": false },
      { "name": "Site B", "value": 43, "gap": 9, "highlight": false },
      { "name": "Site C", "value": 36, "gap": 2, "highlight": false },
      { "name": "Site E", "value": 28, "gap": -6, "highlight": false },
      { "name": "Site D", "value": 21, "gap": -13, "highlight": true },
      { "name": "Site F", "value": 18, "gap": -16, "highlight": true }
    ],
    "benchmark": 34,
    "nccn_target": 40
  },
  "financial_impact": {
    "annual_opportunity": "$280,000/year",
    "math": "$280,000/year = 14.5% avg utilization gap × 2 sites × 26 patients × $73,000 margin difference"
  },
  "clinical_impact": {
    "description": "Standardizing regimen selection across sites could improve patient outcomes.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+18.4 months",
        "description": "Potential PFS improvement with optimized regimen selection"
      },
      {
        "type": "OS",
        "value": "+13.3 months",
        "description": "Potential OS improvement"
      },
      {
        "type": "ORR",
        "value": "+31%",
        "description": "Higher response rates with Dara-based regimens"
      },
      {
        "type": "Equity",
        "value": "+62%",
        "description": "Improved treatment equity across sites"
      },
      {
        "type": "QoL",
        "value": "+22%",
        "description": "Improved quality of life scores"
      }
    ],
    "quantitative": "+18.4 months PFS"
  },
  "peer_comparison": {
    "description": "Top-performing oncology networks maintain <10% variation in RRMM regimen selection across sites vs. your 34% range, representing significant opportunity for standardization.",
    "peer_benchmark": 10,
    "financial_impact": {
      "annual_opportunity": "$380,000/year",
      "math": "$380,000/year = 24% standardization opportunity × 70 patients × $73,000 margin difference × site factor"
    },
    "action_steps": [
      {
        "text": "Implement system-wide RRMM treatment pathways",
        "icon": "document"
      },
      {
        "text": "Create Site D/F improvement task force",
        "icon": "users"
      },
      {
        "text": "Develop cross-site regimen utilization dashboards",
        "icon": "chart"
      },
      {
        "text": "Schedule monthly site director review meetings",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 92,
  "action_steps": [
    {
      "text": "Analyze differences in site-specific practice patterns",
      "icon": "chart-line"
    },
    {
      "text": "Implement Site A best practices across all locations",
      "icon": "document"
    },
    {
      "text": "Create site-specific improvement plans for Sites D and F",
      "icon": "clipboard"
    },
    {
      "text": "Develop standardized order sets across all sites",
      "icon": "document"
    }
  ],
  "suggestions": [
    {
      "text": "Investigate site-specific factors affecting regimen selection",
      "icon": "chart-line"
    },
    {
      "text": "Consider financial incentives for site directors",
      "icon": "chart"
    }
  ],
  "drilldowns": [
    {
      "label": "View by Provider",
      "cohort": "Multiple Myeloma Regimen Selection by Provider",
      "jsonFile": "multiple-myeloma-by-provider.json",
      "drilldownLevel": 1
    },
    {
      "label": "View by Payer",
      "cohort": "Multiple Myeloma Regimen Selection by Payer",
      "jsonFile": "multiple-myeloma-by-payer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Analyze Margins",
      "cohort": "Multiple Myeloma Regimen Margin Analysis",
      "jsonFile": "multiple-myeloma-regimen-margins.json",
      "drilldownLevel": 1
    }
  ]
} 